Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

When mice implanted with metastasis-prone human cancer cells were treated with compounds that targeted ACBP’s activity, none ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

Philips is launching a new clinical trial aimed at reducing the amount of radiation used during coronary procedures, with an ...

A Hong Kong-based developer of a catalog of urine-based tests for cancer, infectious diseases, women’s health and more has ...